Tech Company Financing Transactions
Alzeca Biosciences Funding Round
Private investors joined a $11 million Series A funding round for Alzeca Biosciences. This venture round closed on 8/18/2017.
Transaction Overview
Company Name
Announced On
8/18/2017
Transaction Type
Venture Equity
Amount
$11,000,000
Round
Series A
Investors
private investors (Navneet Puri)
private investors (Peter Werth)
Proceeds Purpose
Alzeca will use the funds to advance the development of its ADx nanoparticle, the first magnetic resonance imaging (MRI) contrast agent targeting amyloid plaques, through Phase 1 human clinical trials.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
1800 Bering Dr. 850
Houston, TX 77057
USA
Houston, TX 77057
USA
Phone
Website
Email Address
Not Recorded
Overview
Alzeca Biosciences is an early-stage company focused on developing novel, proprietary, targeted MRI imaging agents for the early diagnosis of Alzheimer's disease and other neurodegenerative disorders. The company's proprietary technology is based on nanoparticles that specifically bind to abnormal proteins that accumulate in the brain years before significant cognitive symptoms appear.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carlo Medici
VP - Regulatory Affairs
Brenda Fielding
Browse more venture capital transactions:
Prev: 8/18/2017: Ripcord venture capital transaction
Next: 8/18/2017: Wine.com venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs